SCP
OLMA icon

Sender Company & Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Sender Company & Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,793
Closed -$106K – 340
2025
Q3 		$106K Buy
+10,793
New +$64.8K 0.01% 441

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sender Company & Partners's OLMA Position: Q4 2025 in Review

Sender Company & Partners sold out of Olema Pharmaceuticals (OLMA) in Q4 2025, closing a stake of 10,793 shares — an estimated $106K sold.

Sender Company & Partners first reported a position in OLMA in Q3 2025 and held it in 1 quarter. The position peaked at $106K in Q3 2025. 200 funds tracked by Wall St. Rank hold OLMA as of Q4 2025.

  • Sender Company & Partners reported no remaining Olema Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 10,793 Olema Pharmaceuticals shares in Q4 2025, an estimated $106K.
  • Sender Company & Partners first reported a position in Olema Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Sender Company & Partners's Olema Pharmaceuticals position peaked at $106K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.